Proteinuria merupakan faktor prognostik penting dalam progresivitas sindrom nefrotik. Penggunaan ACE-inhibitor dapat mengurangi proteinuria dengan menurunkan tekanan hidrolikglomerular pada kelainan ginjal. Tujuan evidence base case report (EBCR) ini adalah mengevaluasipenggunaan ACE inhibitor terhadap proteinuria pada sindrom nefrotik. Dilakukan pencarianpada database daring di Pubmed®, Cochrane®, Sciencedirect®, Clinical Key®, EBSCO®, danProquest®. Selanjutnya dilakukan skining dengan kriteria inklusi dan eksklusi yang spesifik sertamembaca full text artikel tersebut. Dari pencarian tersebut didapatkan tiga artikel yang relevan.Pada ketiga artikel didapatkan hasil penurunan proteinuria pada pasien sindrom nefrotik secarasignifikan. Pada artikel pertama didapatkan CER 0%, AER 50%, RRR 50%, dan NNT 1,81dengan 95% CI 0,11–0,89. Pada artikel kedua didapatkan ekskresi protein urin setelah 4,8,dan 12minggu pemberian fosinopril menurun secara signifikan terhadap plasebo (p<0,05). Pada artikelketiga didapatkan pemberian lisinopril selama 12 bulan menghasilkan ekskresi protein urin yangsignifikan terhadap baseline (p<0,0001). Pemberian ACE-inhibitor pada pasien dengan sindromnefrotik dapat mengurangi protein urin secara signifikan.Kata kunci: ACE-inhibitor, proteinuria, sindrom nefrotikThe Usage of ACE Inhibitor in Reducing Proteinuria in Nephrotic SyndromeAbstractProteinuria is an important prognostic factor in progressivity of nephrotic syndrome. ACE inhibitor could reduce proteinuria by decreasing glomerular hydraulic pressure in renal disease. To determine the USAge of ACE-inhibitor in reducing proteinuria in nephrotic syndrome. The search wasconducted in various online databases such as Pubmed®, Cochrane®, Sciencedirect®, ClinicalKey®, EBSCO®, and Proquest®, after defining the inclusion and exclusion criteria then screeningthe titles and abstracts and the authors found three relevant articles. All articles were have thesignificant reduction of proteinuria in nephrotic syndrome. In the first article, CER 0%, AER 50%,ARR 50% and NNT 1.81 with 95% CI 0.11–0.89. In second article, the urinary protein excretionafter 4,8, and 12 weeks treated with fosinopril were significantly reduced compared to the placebo(p<0.05). In the third article, the group that receive lisinopril were significantly reducing urinaryprotein excresion compared to the baseline value (p<0.0001). ACE inhibitor could signficantlyreduce proteinuria in nephrotic syndrome.